{"entity":{"id":"alphamab","kind":"company","name":"Alphamab Oncology","aka":["康宁杰瑞","Jiangsu Alphamab Biopharmaceuticals","Alphamab Oncology"],"tldr":"Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.","summary":"Alphamab Oncology, based in Suzhou, founded in 2008 and listed in Hong Kong as 9966.HK, developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003. Envafolimab, sold as Enweida, was approved in 2021; KN026, a HER2 biparatopic bispecific, is in phase 3 in gastric and breast cancer; and JSKN003 and JSKN033, a subcutaneous PD-L1 plus HER2 ADC combination, are in trials, all built on its single-domain antibody platform. OnCo links it to HER2 and PD-L1 as targets and to the envafolimab record. Whether subcutaneous dosing wins meaningful share in a class dominated by intravenous antibodies is the open question. Envafolimab has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.alphamabonc.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":[],"targets":["her2","pdl1"],"drugs":["envafolimab","jskn003","jskn016"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06942234","nct05744427"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.alphamabonc.com/en/","ticker":"9966.HK","founded":2008,"investors":[],"funding":[]},"route":"/companies/alphamab/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"},{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/"},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"}],"trial":[{"id":"nct07283198","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07283198/"},{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/"},{"id":"nct06775483","kind":"trial","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","route":"/trials/nct06775483/"},{"id":"nct06079983","kind":"trial","name":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","route":"/trials/nct06079983/"},{"id":"nct05744427","kind":"trial","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","route":"/trials/nct05744427/"},{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/"}],"company":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/"}]}}